Teresa Legido

Teresa Legido

Auto-generated profile, based on publicly available information

Teresa Legido

Neuropsiquiatria i Addicions, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2023 in Psychiatry Research
Verified
Journal Article
Closed access
ATAlba Toll
Alba Toll
EPEmilio Pechuan
Emilio Pechuan
DBDaniel Bergé
Daniel Bergé
TLTeresa Legido
Teresa Legido
LMLaura Martínez-Sadurní
Laura Martínez-Sadurní
AMAnna Mané
Anna Mané

8 May 2023 in Psychiatry Research
Verified
Journal Article
Open access
ASAlex G Segura
Alex G Segura
AMAnna Mané
Anna Mané
LPLlucia Prohens
Llucia Prohens
NRNatalia Rodriguez
Natalia Rodriguez
GMGisela Mezquida
Gisela Mezquida
SMSergi Mas
Sergi Mas
Cannabis use is highly prevalent in first-episode psychosis (FEP) and plays a critical role in its onset and prognosis, but the genetic underpinnings promoting both conditions are poorly understood. Current treatment strategies for cannabis cessation in FEP are clearly inefficacious. Here, we aimed to characterize the association between cannabis-related polygenic risk scores (PRS) on cannabis use and clinical course after a FEP. A cohort of 249 FEP individuals were evaluated during 12 months. Symptom severity was measured with the Positive and Negative Severity Scale and cannabis use with the EuropASI scale. Individual PRS for lifetime cannabis initiation (PRSCI) and cannabis use disorder (PRSCUD) were constructed. Current cannabis use was associated with increased positive symptoms. Cannabis initiation at younger ages conditioned the 12-month symptom progression. FEP patients with higher cannabis PRSCUD reported increased baseline cannabis use. PRSCI was associated with the course of negative and general symptomatology over follow-up. Cannabis use and symptom progression after a FEP were modulated by cannabis PRS, suggesting that lifetime initiation and use disorders may have partially independent genetic factors. These exploratory results may be the first step to identify those FEP patients more vulnerable to cannabis use and worse outcomes to ultimately develop tailored treatments.

12 January 2024 in Spanish Journal of Psychiatry and Mental Health
Verified
Journal Article
Closed access
RLRaquel López-Carrilero
Raquel López-Carrilero
MMMercedes Lo Monaco
Mercedes Lo Monaco
EFEva Frigola-Capell
Eva Frigola-Capell
MFMarta Ferrer-Quintero
Marta Ferrer-Quintero
LCLuciana Diaz Cutraro
Luciana Diaz Cutraro
Susana OchoaSusana Ochoa
Susana Ochoa